SK9532003A3 - Crystalline forms of atorvastatin calcium - Google Patents

Crystalline forms of atorvastatin calcium Download PDF

Info

Publication number
SK9532003A3
SK9532003A3 SK953-2003A SK9532003A SK9532003A3 SK 9532003 A3 SK9532003 A3 SK 9532003A3 SK 9532003 A SK9532003 A SK 9532003A SK 9532003 A3 SK9532003 A3 SK 9532003A3
Authority
SK
Slovakia
Prior art keywords
intensity
polymorphic form
crystalline polymorphic
calcium
atorvastatin calcium
Prior art date
Application number
SK953-2003A
Other languages
English (en)
Slovak (sk)
Inventor
Der Schaaf Paul Adriaan Van
Fritz Blatter
Martin Szelagiewicz
Kai-Uwe Schoning
Original Assignee
Ciba Sc Holding Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Sc Holding Ag filed Critical Ciba Sc Holding Ag
Publication of SK9532003A3 publication Critical patent/SK9532003A3/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SK953-2003A 2000-12-27 2001-12-19 Crystalline forms of atorvastatin calcium SK9532003A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00811249 2000-12-27
PCT/EP2001/015012 WO2002051804A1 (en) 2000-12-27 2001-12-19 Crystalline forms of atorvastatin

Publications (1)

Publication Number Publication Date
SK9532003A3 true SK9532003A3 (en) 2004-04-06

Family

ID=8175112

Family Applications (1)

Application Number Title Priority Date Filing Date
SK953-2003A SK9532003A3 (en) 2000-12-27 2001-12-19 Crystalline forms of atorvastatin calcium

Country Status (23)

Country Link
US (4) US7538136B2 (cs)
EP (2) EP2000461A1 (cs)
JP (2) JP2004516311A (cs)
KR (1) KR100790766B1 (cs)
CN (1) CN1273449C (cs)
AT (1) ATE420070T1 (cs)
AU (1) AU2002224952B2 (cs)
CA (7) CA2622697A1 (cs)
CZ (1) CZ20032019A3 (cs)
DE (1) DE60137364D1 (cs)
ES (1) ES2319870T3 (cs)
HR (1) HRP20030607A2 (cs)
HU (1) HUP0302519A3 (cs)
IL (1) IL156280A0 (cs)
IS (1) IS6859A (cs)
MX (1) MXPA03005879A (cs)
NO (1) NO20032758D0 (cs)
NZ (1) NZ527048A (cs)
PL (1) PL365312A1 (cs)
PT (1) PT1345896E (cs)
SK (1) SK9532003A3 (cs)
WO (1) WO2002051804A1 (cs)
ZA (1) ZA200304297B (cs)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
PL362472A1 (en) * 2000-11-03 2004-11-02 Teva Pharma Atorvastatin hemi-calcium form vii
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
SK9532003A3 (en) * 2000-12-27 2004-04-06 Ciba Sc Holding Ag Crystalline forms of atorvastatin calcium
ES2558565T3 (es) 2001-06-29 2016-02-05 Warner-Lambert Company Llc Formas cristalinas de sal de calcio del ácido [R-(R*,R*)]-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-fenilamino)carbonil]-1H-pirrol-1-heptanoico (2:1) (atorvastatina)
US7074818B2 (en) 2001-07-30 2006-07-11 Dr. Reddy's Laboratories Limited Crystalline forms VI and VII of Atorvastatin calcium
JP2005500351A (ja) * 2001-07-30 2005-01-06 ドクター・レディーズ・ラボラトリーズ・リミテッド 結晶形態viおよびviiのアトルバスタチンカルシウム
TR200302281T2 (tr) * 2001-08-16 2004-09-21 Teva Pharmaceutical Industries Ltd. Statinlerin kalsiyum tuzu formlarını hazırlamak için işlemler
WO2003018547A2 (en) * 2001-08-31 2003-03-06 Morepen Laboratories Ltd. An improved process for the preparation of amorphous atorvastatin calcium salt (2:1)
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
PL372303A1 (en) * 2002-02-15 2005-07-11 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix
KR20090045419A (ko) 2002-02-19 2009-05-07 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴 헤미-칼슘 용매화합물의 탈용매화
AU2002330735A1 (en) * 2002-09-03 2004-03-29 Morepen Laboratories Limited Atorvastatin calcium form vi or hydrates thereof
EP1424324A1 (en) * 2002-11-28 2004-06-02 Teva Pharmaceutical Industries Limited Crystalline form F of Atorvastatin hemi-calcium salt
CA2508871C (en) * 2002-11-28 2008-09-09 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
CA2627940A1 (en) 2004-03-17 2005-10-06 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form
EP1761489A1 (en) * 2004-03-17 2007-03-14 Ranbaxy Laboratories Limited Crystalline form of atorvastatin hemi calcium
WO2005105738A2 (en) 2004-05-05 2005-11-10 Pfizer Products Inc. Salt forms of atorvastatin
JP4915919B2 (ja) 2004-06-11 2012-04-11 Sbiバイオテック株式会社 インターフェロン産生細胞の活性調節剤
CN1997651B (zh) * 2004-07-16 2012-06-06 力奇制药公司 阿托伐他汀钙的氧化降解产物
CA2672554C (en) 2004-07-20 2012-01-03 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl).beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
CN101048141A (zh) 2004-10-28 2007-10-03 沃尼尔·朗伯有限责任公司 形成非晶形的阿托伐他汀的方法
WO2006048894A1 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Novel crystalline forms of atorvastatin calcium and processes for preparing them.
CA2499047A1 (en) * 2005-03-01 2006-09-01 Apotex Pharmachem Inc. Process for producing atorvastatin hemicalcium
JP5523699B2 (ja) * 2005-04-08 2014-06-18 エギシュ ヂョヂセルヂャール ニルヴァーノサン ミケデ レースヴェーニタールササーグ 新規な結晶性のアトルバスタチンヘミカルシウム塩の多形相
CA2547216A1 (en) * 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
ES2304335T3 (es) 2005-11-21 2010-05-19 Warner-Lambert Company Llc Formas nuevas del acido (r-(r*,r*))-2-(4-fluorofenil)-b,b-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)1h-pirrol-1-heptanoico, de magnesio.
BRPI0610344A2 (pt) 2005-12-13 2016-11-29 Teva Pharma forma cristalizada do atorvastatin hemi-calcium, processo para sua preparação, produto famacêutico derivado e seu uso medicinal
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
WO2008002655A2 (en) * 2006-06-28 2008-01-03 Teva Pharmaceutical Industries Ltd. Crystalline forms of atorvastatin
WO2009007856A2 (en) * 2007-07-11 2009-01-15 Actavis Group Ptc Ehf Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
CN104983702A (zh) * 2015-07-23 2015-10-21 青岛蓝盛洋医药生物科技有限责任公司 一种治疗高胆固醇血症的药物阿托伐他汀钙组合物片剂
JP2019167295A (ja) * 2016-07-04 2019-10-03 ゼリア新薬工業株式会社 1,5−ベンゾジアゼピン化合物カルシウム塩の製造法
WO2025147589A1 (en) 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions, and methods for treating retinal diseases and disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
DK0680320T3 (da) * 1993-01-19 1999-10-25 Warner Lambert Co Stabilt oralt CI-981-præparat og fremgangsmåde til fremstilling deraf
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
AU725424B2 (en) * 1995-07-17 2000-10-12 Warner-Lambert Company Crystalline (R-(R*,R*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5- (1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H- pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
HRP960312B1 (en) 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US7411075B1 (en) * 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
CN1423634A (zh) * 1999-11-17 2003-06-11 特瓦制药工业有限公司 阿托伐他汀钙的多晶型物
CA2391357C (en) * 1999-12-17 2009-01-06 Warner Lambert Research And Development Ireland Limited A process for producing crystalline atorvastatin calcium
PL362472A1 (en) * 2000-11-03 2004-11-02 Teva Pharma Atorvastatin hemi-calcium form vii
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
SK9532003A3 (en) * 2000-12-27 2004-04-06 Ciba Sc Holding Ag Crystalline forms of atorvastatin calcium
WO2002057228A1 (en) 2001-01-17 2002-07-25 Biocon India Limited Atorvastatin calcium
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20814A (sl) 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
ES2558565T3 (es) * 2001-06-29 2016-02-05 Warner-Lambert Company Llc Formas cristalinas de sal de calcio del ácido [R-(R*,R*)]-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-fenilamino)carbonil]-1H-pirrol-1-heptanoico (2:1) (atorvastatina)
JP2005500351A (ja) * 2001-07-30 2005-01-06 ドクター・レディーズ・ラボラトリーズ・リミテッド 結晶形態viおよびviiのアトルバスタチンカルシウム

Also Published As

Publication number Publication date
CN1273449C (zh) 2006-09-06
IS6859A (is) 2003-06-24
CA2623599A1 (en) 2002-07-04
KR20030064880A (ko) 2003-08-02
WO2002051804A1 (en) 2002-07-04
ATE420070T1 (de) 2009-01-15
NO20032758L (no) 2003-06-17
HRP20030607A2 (en) 2005-06-30
JP2009221216A (ja) 2009-10-01
HUP0302519A3 (en) 2008-10-28
US7538136B2 (en) 2009-05-26
US20090281162A1 (en) 2009-11-12
CA2622727A1 (en) 2002-07-04
HUP0302519A2 (hu) 2003-12-29
EP1345896A1 (en) 2003-09-24
KR100790766B1 (ko) 2008-01-03
CA2622697A1 (en) 2002-07-04
CA2431068A1 (en) 2002-07-04
JP2004516311A (ja) 2004-06-03
ES2319870T3 (es) 2009-05-14
DE60137364D1 (de) 2009-02-26
US20030114686A1 (en) 2003-06-19
CA2626317A1 (en) 2002-07-04
CZ20032019A3 (cs) 2003-10-15
NO20032758D0 (no) 2003-06-17
NZ527048A (en) 2004-12-24
CN1483022A (zh) 2004-03-17
IL156280A0 (en) 2004-01-04
CA2431068C (en) 2008-06-10
US20040220255A1 (en) 2004-11-04
EP2000461A1 (en) 2008-12-10
US20060205805A1 (en) 2006-09-14
PL365312A1 (en) 2004-12-27
PT1345896E (pt) 2009-02-19
CA2622477A1 (en) 2002-07-04
CA2623600A1 (en) 2002-07-04
EP1345896B1 (en) 2009-01-07
AU2002224952B2 (en) 2007-04-05
ZA200304297B (en) 2004-08-16
MXPA03005879A (es) 2003-09-10

Similar Documents

Publication Publication Date Title
SK9532003A3 (en) Crystalline forms of atorvastatin calcium
AU2002224952A1 (en) Crystalline forms of atorvastatin
SK7212003A3 (en) Hydrolysis of [R(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy- 5-(1-methylethyl)-3-fenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1- heptanoic acid esters with calcium hydroxide
SK391091A3 (en) Crystalline paroxetine hydrochloride hemihydrate, pharmacuetical composition containing the same and its use
SK20262000A3 (sk) Metánsulfonát paroxetínu v kryštalickej forme, spôsob jeho výroby, farmaceutický prostriedok s jeho obsahom a jeho použitie
US7122681B2 (en) Desolvation process for the production of atorvastatin hemi-calcium essentially free of bound organic solvent
EP2049479A2 (en) Polymorphs of atorvastatin sodium and magnesium salts
EP1345903A1 (en) Crystalline forms of cerivastatin sodium
SK50632006A3 (sk) Spôsob prípravy hemivápenatej soli (E)-7-[4-(4-fluórfenyl)-6- izopropyl-2-[metyl(metylsulfonyl)amino]pyrimidín-5-yl](3R,5S)- 3,5-dihydroxy-6-hepténovej kyseliny
IL186221A (en) Crystalline rosuvastatin intermediate
EP1732886B1 (en) Polymorphs of atorvastatin tert.-butylester and use as intermediates for the preparation of atorvastatin
CN1902194B (zh) 制备非晶态(4r-顺)-6-[2-[3-苯基-4-(苯基氨基甲酰基)-2-(4-氟苯基)-5-(1-甲基乙基)-吡咯-1-基]-乙基]-2,2-二甲基-[1,3]-二噁烷-4-基-乙酸的方法

Legal Events

Date Code Title Description
FB9A Suspension of patent application procedure